Adial Pharmaceuticals, Inc. (ADIL) SEC Filing 8-K Material Event for the period ending Monday, September 24, 2018

Adial Pharmaceuticals, Inc.

CIK: 1513525 Ticker: ADIL

View differences made from one to another to evaluate Adial Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adial Pharmaceuticals, Inc..


Assess how Adial Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adial Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Adial Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ADIL
CIK: 1513525
Form Type: 8-K Corporate News
Accession Number: 0001213900-18-012880
Submitted to the SEC: Mon Sep 24 2018 6:22:26 AM EST
Accepted by the SEC: Mon Sep 24 2018
Period: Monday, September 24, 2018
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: